API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 36 sources · 13 days · First seen · Last updated

Pancreatic cancer awareness and treatment developments

Overview

Medical awareness efforts have focused on pancreatic cancer through initiatives such as the “All Together We Can” campaign by PanCAN. This campaign seeks to raise 250 million US dollars over five years to support research, patient advocacy, and clinical trial access. In conjunction with World Pancreatic Cancer Day, new medical advancements have been reported. The European Commission has authorized the sale of Rasonque (daraxonrasib), developed by Revolution Medicines, for treating adults with metastatic pancreatic adenocarcinoma who have previously undergone systemic therapy. This authorization follows an accelerated assessment by the European Medicines Agency. In the phase III RASolute 302 clinical study, patients treated with the once-daily oral tablet showed a median overall survival of 12.4 to 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The drug also reportedly doubled the median time without disease progression from 3.6 to 7.2 months. The drug works by blocking RAS proteins to inhibit tumor growth and is indicated regardless of the presence of a Ras mutation. While the authorization applies across the EU, EEA, Iceland, Norway, and Liechtenstein, individual member states must determine pricing and reimbursement. In Italy, the Italian Medicines Agency is conducting a rolling review to expedite access, while patient associations in Spain are calling for expedited national funding processes. Technological progress is expanding in the diagnostic and surgical fields. In Spain, the ENDOGROUP at Centro Médico Teknon utilizes laser confocal endomicroscopy (EUS-nCLE) to differentiate between benign and malignant pancreatic cysts with high precision. Additionally, the Hospital Universitario Germans Trias i Pujol in Spain is employing Fujifilm Healthcare’s SYNAPSE 3D technology to create personalized anatomical models, which aids surgeons in planning complex procedures by visualizing tumor-vascular relationships.

Entities

European Medicines Agency · Revolution Medicines · AIFA · Alnylam Germany GmbH · SUD4PANCREAS ODV-ETS

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [HEALTH] 36 sources
    European Commission authorizes daraxonrasib for metastatic pancreatic cancer

    The European Commission has approved daraxonrasib (Rasonque) for metastatic pancreatic cancer, showing it can nearly double median survival rates compared to standard chemotherapy.

  2. [HEALTH] 2 sources
    Medical awareness initiatives focus on pancreatic cancer and acute porphyria

    PanCAN launches a major fundraising campaign for pancreatic cancer research while medical awareness grows regarding the diagnostic challenges of acute porphyria.

Sources

allgaeuer-zeitung.de · antennasud.com · blogsicilia.it · cagliarilivemagazine.it · calabrianews.it · canaledieci.it · citynotizie.it · codirp.it · doctor33.it · espressione24.it · farmaventas.es · greenme.it · ilfattonisseno.it · ilpubblicista.it · ilpuntonotizie.it · iodonna.it · jurnalul.ro · lamilano.it · maravillastereo.com · megafon.si · novinky.cz · opieka.farm · periodicodaily.com · quotidianodibari.it · quotidianodifoggia.it · technoblitz.it · telebari.it · telesveva.it · times.si · tn.nova.cz · ukbnewsroom.de · unmondoditaliani.com · upday.com · vetrinatv.it · vizita.si · zerounotv.it

This summary has been updated 3 times: see revision history